Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M186,992Revenue $M51,584Net Margin (%)42.7Z-Score2.5
Enterprise Value $M191,120EPS $3.2Operating Margin %30.5F-Score5
P/E(ttm))18.5Cash Flow Per Share $3.5Pre-tax Margin (%)30.5Higher ROA y-yN
Price/Book2.410-y EBITDA Growth Rate %3.1Quick Ratio2.4Cash flow > EarningsY
Price/Sales3.85-y EBITDA Growth Rate %9.0Current Ratio2.7Lower Leverage y-yN
Price/Cash Flow7.2y-y EBITDA Growth Rate %1.9ROA % (ttm)12.8Higher Current Ratio y-yY
Dividend Yield %3.5Insider Buy (3m)0ROE % (ttm)28.8Less Shares Outstanding y-yY
Payout Ratio %63.0Shares Outstanding M6,379ROI % (ttm)21.6Gross Margin Increase y-yN

Gurus Latest Trades with PFE

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PFEVanguard Health Care Fund 2014-06-30 Add0.62%$29.02 - $32.4
($30.05)
$ 29.21-3%Add 105.23%14,934,022
PFEJoel Greenblatt 2014-06-30 Add0.27%$29.02 - $32.4
($30.05)
$ 29.21-3%Add 71.59%1,741,314
PFECharles Brandes 2014-06-30 Add0.12%$29.02 - $32.4
($30.05)
$ 29.21-3%Add 5.78%6,075,460
PFERay Dalio 2014-06-30 Add0.06%$29.02 - $32.4
($30.05)
$ 29.21-3%Add 250.56%393,008
PFEMichael Price 2014-06-30 Reduce-0.97%$29.02 - $32.4
($30.05)
$ 29.21-3%Reduce -69.14%107,100
PFEDodge & Cox 2014-06-30 Reduce-0.5%$29.02 - $32.4
($30.05)
$ 29.21-3%Reduce -23.73%48,902,097
PFEJean-Marie Eveillard 2014-06-30 Reduce-0.47%$29.02 - $32.4
($30.05)
$ 29.21-3%Reduce -70.71%2,303,762
PFEJohn Hussman 2014-06-30 Sold Out -0.04%$29.02 - $32.4
($30.05)
$ 29.21-3%Sold Out0
PFEJoel Greenblatt 2014-03-31 Add0.38%$29.66 - $32.75
($31.39)
$ 29.21-7%Add 356.54%1,014,808
PFEJohn Hussman 2014-03-31 Buy 0.04%$29.66 - $32.75
($31.36)
$ 29.21-7%New holding, 17000 sh.17,000
PFEVanguard Health Care Fund 2014-03-31 Reduce-0.48%$29.66 - $32.75
($31.36)
$ 29.21-7%Reduce -40.13%7,276,622
PFEJean-Marie Eveillard 2014-03-31 Reduce-0.19%$29.66 - $32.75
($31.39)
$ 29.21-7%Reduce -22.77%7,866,473
PFEJean-Marie Eveillard 2013-12-31 Add0.16%$28.24 - $32.2
($30.7)
$ 29.21-5%Add 23.07%10,186,005
PFEJoel Greenblatt 2013-12-31 Add0.11%$28.24 - $32.2
($30.7)
$ 29.21-5%Add 241.71%222,280
PFERonald Muhlenkamp 2013-12-31 Add0.05%$28.24 - $32.2
($30.7)
$ 29.21-5%Add 29.15%45,129
PFERay Dalio 2013-12-31 Add0.01%$28.24 - $32.2
($30.7)
$ 29.21-5%Add 102.18%110,408
PFEVanguard Health Care Fund 2013-12-31 Reduce-0.91%$28.24 - $32.2
($30.7)
$ 29.21-5%Reduce -43.19%12,153,122
PFECharles Brandes 2013-12-31 Reduce-0.22%$28.24 - $32.2
($30.7)
$ 29.21-5%Reduce -9.32%5,767,402
PFEDavid Dreman 2013-12-31 Reduce-0.15%$28.24 - $32.2
($30.7)
$ 29.21-5%Reduce -85.73%10,163
PFEDonald Yacktman 2013-12-31 Sold Out -0.01%$28.24 - $32.2
($30.7)
$ 29.21-5%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PFE is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
PFE Ray Dalio 2014-06-30393,0080.010.09+250.56%
PFE Vanguard Health Care Fund 2014-06-3014,934,0220.231.2+105.23%
PFE Joel Greenblatt 2014-06-301,741,3140.030.65+71.59%
PFE David Dreman 2014-06-3013,61500.03+14.88%
PFE Charles Brandes 2014-06-306,075,4600.12.2+5.78%
PFE James Barrow 2014-06-3060,500,0580.952.4+1.01%
PFE Prem Watsa 2014-06-30235,00000.48
PFE Ruane Cunniff 2014-06-3010,98700-0.32%
PFE Ronald Muhlenkamp 2014-06-3041,01900.21-0.36%
PFE Mario Gabelli 2014-06-301,104,0700.020.17-5.28%
PFE John Keeley 2014-06-3089,83900.05-6.31%
PFE Dodge & Cox 2014-06-3048,902,0970.771.4-23.73%
PFE Michael Price 2014-06-30107,10000.39-69.14%
PFE Jean-Marie Eveillard 2014-06-302,303,7620.040.17-70.71%
PFE John Hussman 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


PFE: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
OLSON LAURIE JExecutive Vice President 2014-06-12Sell36,275$29.53-2.1view
Germano Geno JGroup President 2014-06-02Sell30,000$29.68-2.59view
YOUNG JOHN DGroup President 2014-03-17Sell9,000$31.38-7.87view
PFIZER INC10% Owner 2014-03-12Buy272,727$11162.82view
CANGIALOSI LORETTA VSr. Vice President, Controller 2014-03-04Sell102,943$32.05-9.8view
Dolsten MikaelPresident R&D 2014-03-04Sell35,789$32.58-11.26view
SUSMAN SALLYExecutive Vice President 2014-03-04Sell67,585$32.59-11.29view
PFIZER INC10% Owner 2014-02-04Buy227,261$8261.38view
DAMELIO FRANK AExecutive Vice President 2014-01-13Sell131,810$30.82-6.2view
DAMELIO FRANK AExecutive Vice President 2014-01-13Sell28,190$30.86-6.32view

Press Releases about PFE :

    Quarterly/Annual Reports about PFE:

      News about PFE:

      Articles On GuruFocus.com
      Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, MFG Aug 18 2014 
      A Strong Candidate for Investor´s Portfolios Aug 12 2014 
      Legendary Investor Irving Kahn's Top Five Stocks Aug 08 2014 
      Widely Held Guru Stocks Near 52-Week Lows Aug 05 2014 
      Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, UBS Aug 04 2014 
      Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
      Is Ken Fisher a Dividend Growth Investor? Jul 27 2014 
      Diamond Hill Capital Comments on Pfizer Inc Jul 25 2014 
      Dodge & Cox Second Quarter 2014 Commentary Jul 23 2014 
      Pfizer: A Fairly Valued Stock Jul 23 2014 


      More From Other Websites
      [video] What’s Behind the Surge in Pharmaceutical Deals? Aug 25 2014
      Business events scheduled for Tuesday Aug 25 2014
      Business events scheduled for Tuesday Aug 25 2014
      [video] Jim Cramer Says Roche's "Bolt-On" Acquisition Means Big Pharma is Thinking Big Aug 25 2014
      [video] Roche's $8.3 billion deal for InterMune Aug 25 2014
      Multimedia assets now available: ViiV Healthcare receives FDA approval for Triumeq® (abacavir,... Aug 25 2014
      Roche's InterMune Acquisition Underscores How It And Pfizer Are On Different M&A Paths Aug 24 2014
      ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new... Aug 22 2014
      Glaxo, Pfizer’s ViiV Wins Approval for HIV Combo Drug Aug 22 2014
      Heart Doctor Pay Drops To $558K As Interventions Scrutinized Aug 22 2014
      Palbociclib Expanded Access Program Now Open To Eligible U.S. Patients With HR+, HER2- Advanced... Aug 21 2014
      U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary... Aug 21 2014
      FDA clears Eliquis for new use against blood clots Aug 21 2014
      FDA clears Eliquis for new use against blood clots Aug 21 2014
      Contract Researcher Parexel Sees Growth In Biotech Aug 21 2014
      Where Are You Looking For Yield Today? Aug 21 2014
      ELIQUIS Approved for Deep Vein Thrombosis and Pulmonary Embolisms Aug 21 2014
      FDA OKs use of Eliquis to treat leg, lung clots Aug 21 2014
      U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary... Aug 21 2014
      Video: Illumina Partners With Big Pharma Firms Aug 21 2014

      Add Notes, Comments or Ask Questions

      User Comments

      SEENSCO
      ReplySEENSCO - 2 months ago
      PFE is trading at the low end of our short-term valuation range ($29-$36) and significantly below our Fair Value estimate of $42.41.
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK